GW Pharmaceuticals PLCGWP:LSE

5.75 / 1.37%
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Nov 24 2014 13:37 GMT.
GWP:LSE is traded on the London Stock Exchange Alternative Investment Market (Aim)

Consensus recommendation

As of Nov 22, 2014, the consensus forecast amongst 3 polled investment analysts covering GW Pharmaceuticals plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 28, 2014. The previous consensus forecast advised investors to purchase equity in GW Pharmaceuticals plc.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
No opinion0

Share price forecast

The 2 analysts offering 12 month price targets for GW Pharmaceuticals plc have a median target of 390.00, with a high estimate of 430.00 and a low estimate of 350.00. The median estimate represents a -7.09% decrease from the last price of 419.75. View Full Financials

High+1.1 %430.00
Med-8.3 %390.00
Low-17.7 %350.00


Dividend information is not available for GW Pharmaceuticals PLC. View Full Financials

Earnings history & estimates

On Aug 06, 2014, GW Pharmaceuticals plc reported 3rd quarter 2014 losses of -0.032 per share.
The next earnings announcement is expected on Nov 17, 2014. View Full Interim Financials

Average growth rate-28.00%

GW Pharmaceuticals plc reported annual 2013 losses of -0.03 per share on Nov 19, 2013. View Full Annual Financials

Average growth rate+44.05%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement


GW Pharmaceuticals plc had 3rd quarter 2014 revenues of 7.61m. This missed the 467.84m consensus estimate of the 3 analysts following the company. This was 1.12% above the prior year's 3rd quarter results. View Full Interim Financials

Average growth rate+0.83%

GW Pharmaceuticals plc had revenues for the full year 2013 of 27.30m. This was 17.59% below the prior year's results. View Full Annual Financials

Average growth rate+4.49%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.